Forecast

There is no analyst data available for this company.

News Go to news feed

Amplitude hits new 52-week low at $7.54

Amplitude shares fell to a new 52-week low of $7.54, 49% below the high of $14.88 and down 35.7% over the past year; they declined 15.6% just in the past week. Despite the selling pressure, Amplitude beat quarterly estimates, reported organic ARR growth of 15.8% and an improved operating margin. The company is boosting its AI capabilities by acquiring InfiniGrow, analysts raised their recommendation, and the balance sheet shows more cash than debt, while technical indicators point to an oversold condition. » More on de.investing.com
Amplitude and GitHub integrate analytics into developer workflows

Amplitude announced an agent-to-agent integration with GitHub that feeds Amplitude analyses into GitHub Copilot workflows, automatically generates product requirements, and aims to accelerate code creation and ticket generation. It also introduced a Feature Experimentation Custom Agent that provides Amplitude-specific commands for feature flags and experiments. The integration uses the open Model Context Protocol (MCP) to deliver product and customer data; Amplitude reports more than 4,300 customers, strong gross margins, and analysts who expect profitability in 2025 and have raised price targets. » More on de.investing.com
Amplitude focuses on enterprise customers and AI as growth engine

At the Piper Sandler Growth Frontiers Conference, Amplitude presented its refocus on enterprise customers and its evolution into a multi‑product platform, emphasizing AI integration as a central growth driver. The company reported a 20% increase in data ingestion and an improvement in dollar-based net retention from 96% to 104%. Strategic acquisitions and cross-selling are intended to double ARR growth, while competition from providers like Adobe and Google remains a challenge. » More on de.investing.com

Financials

In the last year, Amplitude Surgical had revenue of €106.02m and net profit of €1.53m

(EUR)	2024	YoY
Revenue	106.02m	5.81%
Gross profit	37.2m	4.14%
Net profit	1.53m	96.11%
EBITDA	23.59m	23.97%

Fundamentals

Metric	Value
Market capitalization	€299.85m
Number of shares	47.98m
52-week high/low	€6.30 - €3.06
Dividends	No
Beta	0.12
P/E ratio	195.92
PEG ratio	1.96
P/B ratio	3.13
P/S ratio	2.83

Company profile

Amplitude Surgical SA entwickelt und vertreibt Produkte für die orthopädische Chirurgie. Das Unternehmen bietet eine Reihe von orthopädischen Produkten für die Primär- und Revisionschirurgie zur Behandlung von Pathologien der Hüfte, des Knies und der unteren Extremitäten, vor allem für die Fuß- und Sprunggelenkschirurgie. Es bietet Knie- und Hüftprothesen sowie Implantate für den Fuß und das Sprunggelenk an. Das Unternehmen bietet auch AMPLIVISION, ein computergestütztes chirurgisches System, i.M.A.G.E., ein maßgeschneidertes Einweg-Instrumentensystem, und E.T.O.I.L.E., eine Technologieplattform für anteriore Zugänge, die eine weniger invasive Chirurgie ermöglichen. Darüber hinaus bietet das Unternehmen Instrumente für die Anpassung von Implantaten an. Das Unternehmen vertreibt seine Produkte über ein Netz von Vertriebshändlern und Vertretern in rund 30 Ländern. Das Unternehmen beliefert Patienten, Chirurgen und Gesundheitseinrichtungen. Amplitude Surgical SA wurde 1997 gegründet und hat seinen Hauptsitz in Valence, Frankreich.